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Glucocorticoid therapy is associated
with potentially serious side-effects, but there is no infor-
mation available regarding glucocorticoid requirement







Ten male adult hypopituitary patients with
partial ACTH deficiency, baseline plasma cortisol >
200 nmol/ l but a peak stimulated cortisol < 500 nmol/







Patients were assigned, in a random order, to
a cross-over protocol of treatment for 1 week with
full dose hydrocortisone (10 mg twice daily), half-
dose hydrocortisone (5 mg twice daily), or no treatment.






Following each treatment schedule,
patients underwent an 11-h cortisol day curve (CDC),
and the results were compared with those from the 10






The integrated CDC values were significantly
higher in patients taking a full dose of hydrocortisone




 < 0·001). There was no signifi-










 = 0·13), compared to control subjects. Peak post-
absorption cortisol values were higher in patients
receiving full-dose hydrocortisone treatment com-




 < 0·001). There was no significant
difference in plasma sodium concentration, blood pressure
or corticosteroid-binding globulin between patients on






Adult patients with pituitary disease
and partial ACTH deficiency have a cortisol secretory
pattern comparable to that of healthy controls. Con-
ventional full-dose replacement with 10 mg twice
daily of hydrocortisone produces hypercortisolaemia,
whereas half-dose produces a CDC that is not stati-
stically different from that of healthy controls. The
results suggest that current conventional glucocorti-
coid replacement overtreats patients with partial ACTH
deficiency under normal unstressed physiological
conditions.
 
Adrenocorticotrophin hormone (ACTH) deficiency is a common
manifestation of hypothalamic–pituitary disease, but there is no
unified approach to diagnosis or treatment. The gold standard
method for the diagnosis of ACTH deficiency is the insulin




., 1986). Other provocative tests of










., 1988) are used in some centres. A variety of normal
peak cortisol responses to provocative tests have been reported
by different units, with normal cut-off concentrations quoted






In addition, there is no clear consensus on the optimum
glucocorticoid replacement dose. In the particular case of patients
with partial ACTH deficiency, there is no agreement as to whether
regular maintenance glucocorticoid therapy is needed at all.
Anecdotally, practice varies between full-dose replacement
therapy in some centres, to no glucocorticoid treatment other
than during intercurrent illness in other units. The lack of agreement
on optimum practice is a reflection of the paucity of published
data on the adequacy of different glucocorticoid replacement
regimens. Prescribing the appropriate dose of glucocorticoid is
crucial, as excessive doses are associated with metabolic distur-





., 1952). In this paper we report the cortisol day
profiles of patients with partial ACTH deficiency treated with
full-strength hydrocortisone replacement dose, half-strength
hydrocortisone replacement dose, and no glucocorticoid treat-
ment therapy.
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Male adult hypopituitary patients with partial ACTH deficiency,
defined as a fasting 08·00 h total serum cortisol exceeding
200 nmol/ l with a stimulated peak value of less than 500 nmol/ l,
were identified from the Beaumont Hospital Pituitary Database.
ACTH reserves were assessed fewer than 6 months before the
start of the study in all patients. Our local practice is to use the
ITT as gold standard for the identification of ACTH deficiency,
with glucagon stimulation testing (GST) as an alternative when
the ITT is contraindicated because of seizure disorders or cardiac
disease. A peak cortisol response > 500 nmol/ l is defined in our
laboratory as normal. Because glucagon stimulation is associated
with subnormal cortisol responses in about 8% of healthy subjects
(Rao & Spathis, 1987), patients whose ACTH deficiency was
defined by abnormal response to GST were only included if
they also had both significant GH deficiency (stimulated peak <
3 ng/ml and IGF-1 below age-specified reference range) and
gonadotrophin deficiency, in order to exclude those with false
negative responses to glucagon.
We also excluded patients with severe cardiac or respiratory
disease, patients with terminal illness and patients on antiepilep-
tic therapy or other medications which interfere with hydro-
cortisone metabolism. Female subjects were excluded because of
the potential effect of oestrogen status on corticosteroid-binding
globulin (CBG) levels. We identified 14 patients who fulfilled the
above criteria; 10 agreed to participate in the study. All patients
had pituitary tumours. Eight patients had ACTH deficiency
defined by ITT (nadir glucose value < 2·2 mmol/ l was achieved
in each case) and two patients by GST.
All six nonacromegalic patients had GH deficiency; four
were treated with recombinant human GH. Eight patients were
gonadotrophin-deficient and were on testosterone replacement.
Four patients were on regular maintenance hydrocortisone
treatment prior to starting the study. The four patients with
acromegaly had a mean GH value on a five-point GH-day curve of
less than 2·5 ng/ml, with serum IGF-1 in the normal age-specified
reference range. Clinical details of patients are summarized in
Table 1.
Ten healthy male control volunteers were studied. All patients
and controls gave written informed consent to participate in the





All 10 participating patients were assigned, in a cross-over pro-
tocol, to take conventional full-dose oral hydrocortisone, defined
as 10 mg twice daily, for 1 week; half-dose of oral hydrocortisone,
defined as 5 mg twice daily, for 1 week; and no hydrocortisone
treatment for 1 week. The patients sequentially took each treat-
ment in a random order. On the last day of each treatment schedule,
the subject was admitted to our clinical research centre for a cor-
tisol day curve (CDC), which was a modification of that described
by Trainer & Besser (1995). Patients were admitted at 07·00 h,
following a 12-h fast. A heparinized intravenous cannula was
inserted in a peripheral vein and clotted blood samples for serum
total cortisol measurements were drawn at 08·00, 09·00, 10·00,
11·00, 13·00, 15·00, 17·00, 18·00 and 19·00 h. Hydrocortisone
treatment was given at 08·00 and 17·00 h.
Baseline clotted blood samples were withdrawn for measure-
ment of corticosteroid-binding globulin (CBG), free T4, TSH,
testosterone, prolactin and IGF-1. A lithium–heparin blood
sample was also collected for measurement of plasma sodium
on each the three testing days.
Resting pulse rate (PR) and blood pressure (BP) were measured
on the morning of each of the three testing days. BP was measured














cortisol (nmol/ l) Hormone replacement
1 50 33·2 prolactinoma No GH, GT 258 467 (ITT) T
2 41 25·8 acromegaly Yes GT 228 329 (ITT) T, HC
3 49 27·2 NSA No GH, GT 215 344 (GST) T, rh-GH
4 48 28·7 NSA Yes GH, GT 298 495 (ITT) rh-GH, T
5 60 31 acromegaly Yes GT 215 471(ITT) T, HC
6 41 31·9 acromegaly Yes _ 206 446 (ITT) HC
7 41 38·5 prolactinoma Yes GH, GT 385 442 (ITT) rh-GH, T, HC
8 32 32·5 prolactinoma No GH, GT 282 409 (ITT) T
9 23 24·8 prolactinoma Yes GH, GT 294 418 (GST) rh-GH, T
10 54 37 acromegaly Yes GT 358 494 (ITT) T
Peak cortisol indicates stimulated level after ITT (insulin tolerance test); or GST (glucagon stimulation test). NSA, nonsecretory adenoma; GH, growth 
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with the patient in a supine position using a manual mercury
spygmomonometer. BP value was the mean of three measurements
15 min apart. Patients were specifically asked about any symptoms
of steroid deficiency.
Patients and their next of kin were counselled and given written
information regarding symptoms of glucocorticoid deficiency
and instructed to contact the study co-ordinator promptly if they
developed any of these symptoms or became unwell. Patients had
a 24-h access by telephone to the study co-ordinator.
Ten healthy male controls also had 11-h CDCs. This was done
only once, on no hydrocortisone treatment. Baseline blood samples,




Serum total cortisol was measured using fluoroimmunoassay
(FIA), AutoDELFIA (Perkin Elmer, Turku, Finland) with intra-
assay coefficients of variation (CV) of 3·6%, 2·7% and 3% and
an interassay CV of 1·6%, 1·1% and 1·5%, at serum cortisol con-
centrations of 210, 517 and 781 nmol/ l, respectively. Samples
from each individual were assayed in a single batch in each case.
Serum CBG was measured using radioimmunoassay (Bio-
Source UK Ltd, Nivelles, Belgium). The interassay CV is 6·0%
and 4·9% at CBG concentrations of 24·2 and 112·4 mg/l, respec-
tively. The intra-assay CV is 7·7%, 3·8% and 3·3% at CBG
concentrations of 33·1, 62·2 and 109·4 mg/l, respectively.
Serum total testosterone, FT4, TSH and prolactin were meas-
ured using FIA, AutoDELFIA (PerkinElmer, Turku, Finland),
IGF-1 was measured using HCl-extraction radioimmunoassay
(Nicholas Institute Diagnostics, San Juan Capistrano, CA,
USA). Plasma sodium was measured by ion-selective electrode








) models were used to compare
serum cortisol results of patients on full-dose, half-dose and no
hydrocortisone treatments, and controls at various time periods
and also to compare peak and trough cortisol values between
patients and controls. Multiple comparison tests using a Bonfer-
roni correction factor was used to determine if results reached




-test was used to com-
pare body mass index (BMI), PR, BP, plasma sodium and CBG





0·05 were taken as significant. Stata (version 8, Stata Inc., College




Patients and control subjects were matched for age, BMI and
CBG values (Table 2).
Figure 1 shows the mean CDCs of the patients and controls.









 0·37) were not significantly different to
the integrated CDC of the controls. The cortisol profile of patients
on no treatment closely resembled that of healthy controls (Fig. 1).
The integrated CDC was significantly higher when patients took





Peak postabsorption serum cortisol was significantly higher in





there was nonsignificant difference in peak cortisol between









 0·37), compared to controls. Trough cortisol values were
not significantly different in patients on any of the treatment
schedules, when compared to controls (Table 3).
All 10 patients remained well throughout the duration of the
study. Pulse rate, systolic BP and diastolic BP were similar on
all treatment schedules, and did not differ between patients and
the controls (Table 3). All patients and controls had serum
IGF-1, thyroid function, testosterone and prolactin values in




This the first study to examine the serum cortisol profiles of male
adult hypopituitary patients with partial ACTH deficiency both
on and off glucocorticoid treatment. It has previously been sug-
gested that a basal posthypophysectomy cortisol level of greater
than 250–270 nmol/ l  is safe, based on the assumption that this









., 2000). Our data, which were
collected in patients with baseline serum cortisol of > 200 nmol/ l,
 
Patients, n = 10 Controls, n = 10 P-value
Age (years) 43·9 ± 10·8 38·9 ± 12·2 0·34
BMI (kg/m2) 31·1 ± 4·5 30·8 ± 4·3 0·88
CBG (mg/l) 41·7 ± 7·1 44·9 ± 4·6 0·25
Baseline cortisol 273·9 ± 61·8 357·3 ± 84·4 0·021
Peak stimulated cortisol 432·9 ± 58·9
Results presented as mean ± SD. BMI, body mass index; CBG, corticosteroid-binding globulin.
Table 2 Baseline characteristics of patients and 
controls
 














show that the daytime cortisol profile, without treatment, is
comparable to that of healthy subjects. We used this basal cortisol
level for recruitment purposes, based on our (unpublished) obser-
vation that patients with pituitary disease who have a basal serum
cortisol > 200 nmol/ l, and who are not receiving glucocorticoid
replacement, do not present with symptoms or signs of cortisol
deficiency under unstressed conditions.
Historically, the glucocorticoid replacement dose for patients
with adrenal insufficiency was 30 mg of oral hydrocortisone
daily, given in divided doses (Besser & Jeffcoate, 1976). How-
ever, the daily cortisol production rate was subsequently shown








., 1991), prompting a reap-
praisal of the optimum glucocorticoid replacement doses and a
reduction in the mean recommended dose of hydrocortisone




., 1997). Our data show
that, in patients with partial ACTH deficiency, 20 mg of hydro-
cortisone, given in divided doses of 10 mg twice daily, produces
two supraphysiological peaks in serum cortisol concentration,
and an integrated CDC statistically higher than that of healthy
controls. We have also shown that low-dose hydrocortisone ther-
apy produces a cortisol profile similar to that of healthy controls.
Our results suggest that current conventional hydrocortisone
replacement doses are supraphysiological for patients with
partial ACTH deficiency, and a further appraisal of optimal
glucocorticoid replacement doses is indicated.
In this study, we used twice daily hydrocortisone, which reflects
our clinical practice. This is the most common regimen used in
clinical practice, though some authors have advocated dividing









., 1997). This last regimen produces higher trough




., 1988; Howlett, 1997),
and lower peak concentrations (Howlett, 1997). Although we
have not studied the CDCs on the trice daily regimen, our data
suggest that, for patients with partial ACTH deficiency, twice-
daily low-dose hydrocortisone is sufficient to mimic normal
cortisol day profiles, such that more frequent dosage regimens are
not needed. Indeed, our data show that even without hydrocorti-
sone replacement, the trough serum cortisol concentrations are
similar to physiological troughs in healthy controls, suggesting
that in partial ACTH deficiency, routine glucocorticoid replace-
ment may not be necessary under unstressed conditions.
These findings are particularly important because there is
increasing evidence that even minor over-replacement with
glucocorticoids may have detrimental side-effects. Patients with
primary or secondary adrenal insufficiency taking a mean hydro-
cortisone dose of 29·5 mg daily were shown to have a 19% rise
in serum osteocalcin concentrations after a hydrocortisone dose




., 1997); the authors con-
cluded that even mildly excessive doses of corticosteroids could
have adverse effects on bone formation with possible long-term
implications for the development of osteoporosis. Patients with
adrenal insufficiency receiving 15 or 20 mg of hydrocortisone,
or 0·1 mg/15 kg body weight of dexamethasone, have low serum





., 2003); the authors suggested that this finding is
Fig. 1 Cortisol day curves for patients and controls. Time expressed in 
hours and serum cortisol expressed in nmol/ l. FD, full treatment (10 mg 
twice daily); HD, half-dose (hydrocotisone 5 mg twice daily); NT, no 
hydrocortisone treatment.
Table 3 Peak and trough cortisol values during the cortisol day curves, and clinical parameters of patients and controls
 
Patients 
Controls P-valueFD HD NT
Peak cortisol (nmol/ l) 508·6 ± 86 424·3 ± 93·9  323 ± 74·2 357·3 ± 84·5 < 0·001
Trough cortisol (nmol/ l) 149·8 ± 49·1 165·6 ± 71·7 180·5 ± 64·1 164·4 ± 35·1  0·69
Pulse rate(beats /minutes) 68·2 ± 3·4 66·6 ± 3·1 67·9 ± 2·4 66·9 ± 2·7  0·46
Systolic BP (mmHg) 129.5 ± 12·4 134·3 ± 14·5 131·1 ± 9·6 131·1 ± 10·5  0·84
Diastolic BP (mmHg) 83·4 ± 8·7 83·7 ± 10·7 79·1 ± 11·6 83·9 ± 8·3  0·66
Plasma sodium (mmol/ l) 140·5 ± 1·7 140·2 ± 1·7 141·2 ± 2·2 139·2 ± 1·5  0·11
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consistent with evidence of suppression of the bone remodelling
cycle. Male hypoadrenal patients treated with standard glucocor-
ticoid replacement have also been shown to have reduced bone




., 1994). The potential risk
for osteoporosis is particularly important in patients with hypo-
pituitarism, who may also be deficient in GH and sex steroids,
which augment any tendency to reduced BMD. For protection
against the development of osteoporosis in hypopituitary patients
it is important therefore not to prescribe supra-optimal glucocor-
ticoid replacement doses.
Excess glucocorticoid therapy may also have disadvantageous
metabolic consequences. Hypopituitary patients on glucocorti-
coid replacement showed reduced insulin sensitivity and dimin-
ished glucose tolerance on the mornings when hydrocortisone





., 1995). As their data indicated a decrease in
insulin sensitivity with standard hydrocortisone doses, the authors





. (2001) showed that a cohort of hypopituitary
patients treated with a mean daily dose of hydrocortisone of
20 mg had a lower prevalence of impaired glucose tolerance and
diabetes than that reported in hypopituitary patients prescribed





They speculated that the lower prevalence of abnormal glucose
tolerance in their cohort may have reflected the lower glucocor-
ticoid replacement doses. There is also evidence that glucocor-
ticoid treatment is associated with a dose-related increase in the




., 2003), with no
safe dose threshold below which there is no excess risk. Recent
epidemiological data suggest that there is increased vascular
mortality in hypopituitary patients, which may be partly related






Glucocorticoid therapy is well recognized to cause ocular





intraoccular pressure was found to be higher in hypoadrenal
patients following 20 mg of morning hydrocortisone when





intraocular pressures remained within normal limits, the authors
concluded that even minor degrees of glucocorticoid excess may
have adverse implications for intraocular pressure.
Our patients remained symptomatically well during the short
study period. Another study has found no effect on quality of life
with the reduction of hydrocortisone dose from 30 mg to 15 mg






Assessment of glucocorticoid replacement in routine clinical
practice tends to be arbitrary and based on a synthesis of clinical
well being, electrolyte measurement and out-patient blood
pressure readings. A simple and highly sensitive biological
maker, similar to TSH for thyroxine replacement in primary
hypothyroidism, does not exist. Twenty-four-hour urinary free
cortisol estimation is occasionally used, but is not a reliable indi-
cator of the optimal hydrocortisone replacement dose (Monson,




., 1976; Trainer &
Besser, 1995) has been suggested to be an accurate tool for
assessing optimal hydrocortisone replacement. However, the
accuracy of this method is increased by frequent sampling and
we would recognize that physiological peak serum ACTH and
cortisol concentrations occur in the early hours of the morning,
between 06·00 and 08·00 h (Torpy & Jackson, 2001). Patients
with severe ACTH deficiency are particularly vulnerable to
symptoms at this time if glucocorticoid replacement is inade-
quate. However, the basal 08·00 h serum cortisol concentrations
in our patients with partial ACTH deficiency, were similar on
all three study days, suggesting that the hydrocortisone dosage
regimen did not effect the basal morning serum cortisol concen-
trations. This is probably due to the rapid clearance of hydro-
cortisone taken on the previous evenings. This suggests that
over-replacement with hydrocortisone during the day does not
lead to higher morning serum cortisol concentrations, and there-
fore may not be safer for patients with partial ACTH deficiency.
It could be postulated that supraphysiological serum cortisol
peaks suppress endogenous ACTH production, and therefore,
slightly excessive glucocorticoid replacement may not lead to
significant over-exposure to glucocorticoids. Our data do not
support this argument, however, as trough cortisol levels were
not significantly lower when patients are treated with full-dose
hydrocortisone therapy. This indicates that, despite the short half-
life of hydrocortisone, conventional replacement doses do lead
to genuine over-exposure to excess glucocorticoids. This observ-
ation that trough cortisol was not significantly different from
controls, even when patients were on no treatment, is reassuring
that lower than conventional doses of glucocorticoid therapy will
not expose patients to the risk of hypocortisolaemia. In addition,
parameters that reflect corticosteroid action such as plasma
sodium and BP remain unchanged, indicating that corticosteroid
withdrawal was not causing short-term harm.
This was a short-term study and it would therefore be prema-
ture to suggest that it is safe to withhold treatment in patients
with partial ACTH deficiency on the basis of our data alone. Some
patients with partial ACTH deficiency may progress to severe
ACTH deficiency as a result of the recurrence of their under-
lying pituitary disease or the progressive effects of radiotherapy.
Patients who develop intercurrent illness may be particularly
susceptible to acute adrenal crises if they are not on maintenance
corticosteroids, and may inadvertently omit stress doses of gluco-
corticoid treatment. In addition, the results of this study cannot
be extrapolated to situations of more severe ACTH deficiency, in
which the use of full glucocorticoid replacement dosage is justified.
These data should prompt a reappraisal of the appropriate
replacement dose of glucocorticoid, particularly with the gathering
 














evidence that even marginally excessive glucocorticoid doses
could be associated with significant morbidity. Patients with
partial ACTH deficiency may be better treated with hydrocortisone
5 mg twice daily than full doses, or may not even need gluco-
corticoid treatment other than during acute illness. Certainly our
data suggest that a longer-term prospective trial of lower doses
of hydrocortisone therapy, or even no therapy at all, would be
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